Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Mitiglinide, a benzylsuccinic acid derivative, exerts selective action on the ATP-dependent K
(KATP) channel of pancreatic β-cells and reportedly possesses a stronger affinity to the
channel compared with other insulinotropic sulphonylurea receptor ligands, namely repaglinide
and nateglinide. Preprandial administration of mitiglinide efficiently reduces postprandial
hyperglycemia and improves overall glycemic control.
This was a 12-week, open, randomized study for comparing Mitiglinide versus Acarbose. The
purpose of this study is to evaluate the efficacy and safety of Mitiglinide vs Acarbose in
patients with type 2 diabetes mellitus.